Interleukin-6 (IL-6) promotes growth of human multiple myel-CDK4, pRB, and p16 have been demonstrated in multiple oma (MM) cells via phosphorylation of retinoblastoma protein human cancers. [16][17][18][19][20][21] [22] [23] [24] To date, however, the functional signifi-(pRB). We therefore examined the kinetics of cyclin-dependent cance of CDK4/pRB/p16 during IL-6-mediated MM cell kinase 4 (CDK4), p16 INK4A , and pRB activation during IL-6-growth has not been characterized.
Mononuclear cells (MCs) were isolated from bone marrow of four patients with MM and peripheral blood of three patients with PCL by Ficoll-Hypaque (FH) density gradient centrifugIntroduction ation, and incubated with HB7 (anti-CD38) monoclonal antibody (MoAb)-biotin-streptavidin and 2H4 (anti-CD45RA) Interleukin-6 (IL-6) is a growth factor for human multiple MoAb-fluorescein isothiocyanate on ice. 25 Two patients each myeloma (MM). 1 Specifically, Kawano et al 2 initially proposed had Durie Salmon stage II and III MM. The percentage of an autocrine IL-6-mediated growth mechanism since some CD38 + CD45RA − cells ranged from 26 to 76% in bone marrow MM cells secrete and proliferate in response to IL-6 in vitro.
mononuclear cells in MM and peripheral blood mononuclear In addition, triggering of MM cells via their cell surface CD40 cells from PCL. Tumor cells were isolated using an Epics C induces IL-6-mediated autocrine growth. 3, 4 Bone marrow stroCell Sorter (Coulter Electronics, Hialeah, FL, USA) (96 ± 2% mal cells (BMSCs) also secrete IL-6; 5-7 moreover, adhesion of CD38 + CD45RA − ), washed, and resuspended in RPMI-1640 MM cells to BMSCs upregulates IL-6 transcription and promedia (Sigma Chemical, St Louis, MO, USA) containing 10% duction by BMSCs, [8] [9] [10] [11] supporting paracrine IL-6-mediated fetal bovine serum (FBS), l-glutamine (L-glu) (GIBCO, Grand tumor cell growth. In reponsive tumor cells, we have preIsland, NY, USA), 100 U/ml penicillin (pen), and 100 g/ml viously shown that IL-6 promotes phosphorylation of retinostreptomycin (strep) (GIBCO). blastoma protein (pRB).
12 To date, upstream signaling pathways regulating pRB phosphorylation during IL-6-mediated tumor cell growth have not been defined.
Immunoprecipitation and Western immunoblotting
Phosphorylation of pRB and related G1 to S phase transition is triggered by activation of cyclin D-cyclin-dependent kinase Immunoprecipitation and Western immunoblotting were per-4 (CDK4)/CDK6 or cyclin E-CDK2 complexes.
13 Cyclinformed as previously reported. 26 alone.
Density ppRB/dpRB expression was assessed by densitometry.
Reagents
( Table 1 and Figure 1 ). CDK4 and pRB were constitutively expressed in all patient MM and PCL cells. CDK4 was more IL-6 (Kirin-Brewrey, Minato-ku, Tokyo, Japan) was added to weakly expressed in MM cells than in PCL cells. Both phoscultures of MM and PCL patient cells, and the effects on kinphorylated and dephosphorylated pRB were present in patient etics of cell cycle regulatory proteins were assayed. Immuno-MM cells, but phosphorylated pRB was predominant in precipitation and Western immunoblotting were done using patient PCL cells. p16 protein was expressed in patient MM these Abs: ZJH murine anti-p16 MoAb; rabbit anti-CDK4 polycells but was not detectable in patient PCL cells. clonal Ab, rabbit anti-CDK6 polyclonal Ab, and rabbit anticyclin D2 polyclonal Ab (Santa Cruz Biotechnology, Santa Cruz, CA, USA); and murine anti-pRB MoAb (Oncogene Science, Uniondale,NY, USA). Densitometry of phosphorylated RB (ppRB)/dephosphorylated RB (dpRB) was measured as in previous studies. 28 Cell cycle analysis Patient MM cells (1 × 10 6 /ml) were cultured in 10% FBS RPMI-1640 media for 1, 3, 6 and 9 days with or without IL-6 (10 ng/ml). Cell cycle distribution was determined by propidium iodide (PI) staining and FACS analysis as in previous reports. 29 Cells were collected and resuspended in 0.5 ml of 3.4 mm sodium citrate, 10 mm NaCl, 0.1% NP-40, and 50 mg/ml PI to stain nuclear DNA. Cell cycle distribution for each sample (1 × 10 4 cells) was determined using the Coulter Epics 753 cell sorter and program M Cycle software (Coulter Electronics).
Results

IL-6 responsiveness and expression of CDK4, pRB and p16 in patient MM and PCL cells
To assess their responsiveness to IL-6, patient tumor cells were cultured in the presence or absence of IL-6, and DNA synthesis was monitored using 3 H-TdR uptake during the last 18 h of 4-day cultures (Table 1 ). Significant proliferation (defined To assay for CDK4, pRB and p16 expression, total cell lysculture with or without IL-6 (10 ng/ml). Lysates were immunoprecipitates were immunoprecipitated with CDK4, pRB or p16 ated with anti-CDK4, pRB or p16 MoAb, followed by Western immunoblotting with the same Abs.
MoAbs, followed by immunoblotting with the same Abs Effects of IL-6 on expression of CDK4, pRB and p16 in patient MM and PCL cells
We next examined changes in CDK4, pRB and p16 protein expression in patient tumor cells in short-term (1 day) and longer term (9 day) cultures with IL-6. As can be seen in Figure 1 , CDK4 expression was lower in IL-6 responsive MM cells than in IL-6 nonresponsive PCL cells in the absence of IL-6. Significant increases in CDK4 expression and pRB phosphorylation were observed at day 1 in IL-6 responsive MM cells, but not in IL-6 unresponsive PCL cells. Densitometry confirmed marked shifts to phosphorylated pRB triggered by IL-6 in MM cells, but not in PCL cells (Table 1 ). In contrast, at day 1, IL-6 did not alter expression of p16 protein in IL-6 responsive MM cells or induce p16 in those IL-6 nonresponsive PCL cells. A longer term (9 day) culture was next done to correlate changes in CDK4 and p16 expression with IL-6 responsiveness. As can be seen in Figure 2a , SI of three IL-6 responsive MM patient cells peaked on day 3 and decreased on days 6 and 9, even though IL-6 was replenished daily. In contrast, IL-6 did not significantly increase SI of nonresponsive PCL cells during the 9-day culture period (Figure 2a ). The number of IL-6 responsive MM cells increased at day 3 and remained stable to day 9 in the presence of IL-6; no increase in cell number was noted in cultures with media alone (Figure 2b ). In cultures of IL-6 unresponsive PCL cells, the cell number gradually and similarly increased to day 9 in cultures in media alone or with IL-6.
In IL-6 responsive MM cells, IL-6 induced an increase in CDK4 expression on day 1 which was sustained from days 1 to 9, as well as a progressive increase in p16 protein expression during the 9-day culture ( Figure 3) . No similar changes in CDK4 or p16 protein expression were observed in cultures in media alone (data not shown). In contrast, the prominent CDK4 expression and lack of p16 protein in IL-6 unresponsive PCL cells was unaltered during 9-day cultures with IL-6 ( Figure 3 ).
Effects of IL-6 on p16 binding to CDK4 or CDK6; cyclin D2 binding to CDK4, CDK6 and pRB; phosphorylation of pRB; and cell cycle profile in patient MM and PCL cells
In order to determine the functional relevance of p16 upregulation observed above in IL-6 responsive MM cells, we next returned to baseline at days 6-9. In IL-6 unresponsive patient PCL cells, in contrast, p16 binding to CDK4 and CDK6 remained undetectable during 9-day culture with IL-6. Moreover, IL-6 did not alter the constitutive cyclin D2-CDK4 or which peaked on days 1-3; the fraction of cells in G1 returned to baseline levels (equivalent to those seen in media at day 0) CDK6 and cyclin D2-pRB binding or the expression of phosphorylated pRB in these PCL cells.
by day 9, despite the presence of IL-6. In contrast, in patient PCL cells, there was a gradual increase in cells in S phase to The effects of IL-6 on cell cycle distribution of patient MM and patient PCL cells were next determined (Table 2) . In day 9, but no significant difference between cells cultured with or without IL-6. patient MM cells, IL-6 triggered a shift from G1 to S/G2M
Figure 3
Long-term effects of IL-6 on expression of CDK4 and p16 proteins in patient MM and PCL cells. Total lysates from patient MM cells (MM 1-4) and patient PCL cells (PCL 1-3) were prepared at day 0 (before) and at days 1, 3, 6 and 9 of culture in 10% FBS RPMI-1640 media with IL-6 (10 ng/ml). IL-6 was replenished daily. Lysates were immunoprecipitated with anti-CDK4 Ab or p16 MoAb, followed by Western immunoblotting with the same Abs.
Discussion
present in patient MM cells but was not detectable in patient PCL cells. Our preliminary studies, as well as recent reports, [22] [23] [24] suggest that the lack of p16 protein in patient PCL cells results In this study we characterized the kinetics of G1 cell cycle regulatory proteins CDK4, pRB and p16 in IL-6 responsive from inactivation of p16 gene by methylation, rather than p16 gene deletion as in ALL. [35] [36] [37] [38] [39] Moreover, it appears that loss of patient MM cells compared with IL-6 nonresponsive patient PCL cells. Expression of CDK4 was lower in patient MM cells p16 correlates with adverse prognosis, since p16 was present in MM cells but not in PCL cells. In the present study, both than in PCL cells; however, CDK4 was upregulated by IL-6 in MM but not in PCL cells. Previous studies have shown that phosphorylated and dephosphorylated pRB were expressed in p16-positive protein MM cells; in contrast, pRB was predomi-IL-6 can regulate transcription factors, ie Fos/AP-1, 30 ,31 which in turn regulate CDK4 expression.
322, 33 Therefore, IL-6 may nantly phosphorylated in PCL cells which lacked detectable p16 protein. Since p16 competes with cyclin D for binding to affect MM cell growth, at least in part, via its effects on CDK4. In addition, overexpression or gene amplification of CDK4 are CDK4/CDK6 and results in dephosphorylation of pRB and G1 growth arrest, the presence of p16 protein in MM cells might known mechanisms of abnormal responses to cytokines 34 and dysregulated growth. 20, 21 Therefore, it is possible that correlate with the more indolent clinical course than in PCL.
In this study we found that IL-6 responsiveness was restricconstitutive overexpression of CDK4 in patient PCL cells is associated with their loss of IL-6 responsiveness.
ted to MM cells expressing p16 protein and that patient PCL cells in which p16 protein was undetectable did not respond Homozygous deletion of p16 gene is frequently observed in primary lymphoid malignancies [35] [36] [37] [38] and in particular is to IL-6. To test the functional significance of CDK4/pRB/p16 in MM cells, we therefore examined the kinetics of these cell associated with adverse prognosis in acute lymphoblastic leukemia (ALL). 39 In our study, we found that p16 protein was cycle regulatory proteins during 9-day cultures with IL-6. In
Figure 4
Effects of IL-6 on p16 binding to CDK4 and CDK6; cyclin D2 binding to CDK4, CDK6 and pRB; and phosphorylation of pRB in patient MM and PCL cells. Total lysates from patient MM cells (left) and patient PCL cells (right) were prepared at day 0 (before) and at days 1, 3, 6 and 9 of culture in 10% FBS RPMI-1640 media with IL-6 (10 ng/ml). IL-6 was replenished daily. Lysates were immunoprecipitated with anti-CDK4 Ab (a), anti-CDK6 Ab (b), anti-cyclin D2 Ab (c and d), or anti-pRB MoAb (e and f) followed by Western immunoblotting with antip16 MoAb (a and b), anti-CDK4 Ab (c) and anti-CDK6 Ab (d), anti-cyclin D2 Ab (e), or anti-pRB MoAb (f). IL-6 responsive cells, IL-6 triggered a rapid upregulation of ated pRB at days 1-3, with return to baseline levels of phosphorylated and dephosphorylated pRB by day 9. These data CDK4 and a more gradual increase in p16. Cyclin D2 binding to CDK4/CDK6 and pRB peaked on days 1-3; in contrast, p16
suggest that upregulation of p16 protein is associated with delayed growth arrest of IL-6-stimulated MM cells in a negabinding to CDK4/CDK6 increased to day 9. These results suggest that the increased CDK4 levels triggered by IL-6 overtive feedback loop and may, at least in part, explain why MM can be a slowly progressive disease in spite of high levels of came p16 protein-related suppression early (days 1-3), but that the progressive increase in p16 without further increments IL-6 production in the bone marrow. A recent report by Kawano and colleagues 24 shows that p16 expression is restricin CDK4 resulted in a shift from cyclin D2-CDK4/CDK6 at days 1-3 to p16-CDK4/CDK6 complex formation at days 6-ted to mature (VLA-5 + MPC-1 + ) plasma cells, suggesting that there may also be heterogeneity of p16 expression within 9. In parallel, both phosphorylated pRB and dephosphorylated pRB were present initially; IL-6 triggered a shift to phosphorylpatient MM cells.
